Medtronic (MDT) Stock Surges 9% After Strong Q1 Results and Robotics Expansion

Key Highlights

• Medtronic shares surged more than 9% in premarket trading following a Q1 earnings and revenue beat
• The company reported adjusted EPS of $1.45, surpassing the analyst estimate of $1.39; revenue reached $9.76B versus expectations of $9.55B
• A $700M strategic investment secured distribution rights for Cornerstone Robotics’ Sentire surgical platform in international markets
• The medical device leader boosted its fiscal 2027 organic revenue growth forecast to 7.25%-7.75% from the previous 6.75%-7.25%
• The cardiovascular division delivered exceptional performance with revenue climbing 19.5% to $3.93B, driven by 88% growth in pulsed field ablation offerings

Shares of Medtronic experienced a significant premarket rally on Tuesday, climbing over 9% to reach $95.20, following the medical technology company’s release of fiscal first quarter results that exceeded Wall Street’s projections for the period ending July 31.

Medtronic plc, MDT

On an adjusted basis, the company delivered earnings of $1.45 per share, representing year-over-year growth from $1.26 and surpassing the consensus estimate of $1.39. Total revenue advanced 14% to $9.76 billion, exceeding analyst projections of $9.55 billion.

All business segments outperformed expectations. The strong performance mirrored similar positive results from industry competitors Abbott and Boston Scientific, both of which also topped analyst forecasts for the quarter.

The cardiovascular division, which represents Medtronic’s largest business unit, delivered particularly impressive results. This segment posted revenue growth of 19.5% to reach $3.93 billion, powered by an extraordinary 88% surge in its pulsed field ablation product line, which addresses cardiac arrhythmias.

Management highlighted that approximately $570 million of the revenue increase stemmed from an additional week included in the quarterly reporting cycle.

Looking ahead, the company upgraded its fiscal 2027 projections. The organic revenue growth target now stands at 7.25% to 7.75%, representing an upward revision from the previous guidance range of 6.75% to 7.25%. The full-year adjusted EPS outlook was refined to a range of $5.94 to $6.00, with the midpoint exceeding Street expectations by two cents.

Major Strategic Investment in Robotic Surgery Technology

While the quarterly results impressed, Medtronic’s strategic expansion into robotic surgery may prove to be the more significant development for long-term investors.

The medical device manufacturer revealed a $700 million strategic investment that secures exclusive distribution rights for Cornerstone Robotics’ Sentire surgical platform in designated international markets excluding the United States.

This addition will be marketed alongside Medtronic’s current Hugo robotic-assisted surgery system. The Hugo platform already competes directly with Intuitive Surgical’s market-leading Da Vinci robotic system.

Shares of Intuitive Surgical declined 0.2% in premarket activity on Tuesday.

According to Medtronic, combining both robotic platforms will serve to “expand access to robotic-assisted surgery and offer surgeons and health systems more choice and flexible solutions.”

Other Strategic Moves and Spinoff Performance

The company also revealed an $80 million stake in Pi-Cardia, which develops heart valve repair technology, alongside an option to fully acquire the business for $210 million.

MiniMed, Medtronic’s former diabetes division that was separated last year and commenced public trading in March, delivered strong quarterly performance as well. MiniMed posted net sales growth of 17% to $843 million, surpassing the analyst consensus of $826.8 million.

MiniMed shares advanced 1.4% in premarket trading.

Prior to Tuesday’s session, Medtronic stock had been down 5.6% year-to-date. The premarket surge positions the stock to reclaim a substantial portion of those losses.

With cardiovascular segment revenue of $3.93 billion for the quarter, this division continues to serve as the company’s primary growth engine as it progresses through fiscal 2027.

The post Medtronic (MDT) Stock Surges 9% After Strong Q1 Results and Robotics Expansion appeared first on Blockonomi.